IPO - Silexion Therapeutics Corp

Form Type: S-1/A

Filing Date: 2025-03-27

Corporate Action: Ipo

Type: Update

Accession Number: 000117891325001087

Filing Summary: Silexion Therapeutics Corp has filed an amendment to its registration statement for an initial public offering. This filing involves the resale of up to 2,377,030 ordinary shares by named securityholders, which are issuable upon the exercise of warrants. Following a 1-for-9 reverse share split that took effect on November 29, 2024, all share amounts and related options have been adjusted accordingly to reflect this change. The company, which is registered in the Cayman Islands, will not receive proceeds from the sale of shares by securityholders, but may gain proceeds from warrant exercises if not done on a cashless basis. The ordinary shares and warrants are traded on Nasdaq under the symbols 'SLXN' and 'SLXNW'. The prospectus outlines risks and uncertainties related to investing in these securities and emphasizes the need for potential investors to review these factors carefully.

Form Type: S-1

Filing Date: 2025-02-12

Corporate Action: Ipo

Type: New

Accession Number: 000117891325000443

Filing Summary: Silexion Therapeutics Corp is preparing for an initial public offering (IPO), with the document dated February 12, 2025. The offering includes the issuance of ordinary shares and involves various financial elements such as callable preferred stock, pre-funded options, and potential related party transactions. The exercise price for the pre-funded options is set at $0.027 per share. Additionally, the document outlines potential legal and management expenses related to its IPO process. The anticipated revenue from the IPO and subsequent funding is expected to contribute significantly to the company’s operational growth and development initiatives. Furthermore, under a sponsorship agreement, Silexion is related to Moringa Acquisition Corp, suggesting a structured partnership to facilitate the IPO.

Form Type: 424B4

Filing Date: 2025-01-17

Corporate Action: Ipo

Type: New

Accession Number: 000117891325000141

Filing Summary: Silexion Therapeutics Corp is conducting an initial public offering (IPO) of 2,145,998 ordinary shares at a public offering price of $1.35 per share, alongside 3,703,703 ordinary warrants. Additionally, 1,557,705 pre-funded warrants are being offered to certain purchasers to avoid ownership exceeding 4.99%. Each pre-funded warrant is priced at $1.3499 and is immediately exercisable for one ordinary share. The closing price of ordinary shares as of January 10, 2025, was $1.94. The company has entered into an agreement with H.C. Wainwright & Co. as the exclusive placement agent for this offering, with a fee structure based on the gross proceeds raised. They plan to use the funds for working capital and business enhancements. A reverse share split of 1-for-9 was effective November 29, 2024, and the company is subject to compliance requirements for continued listing on Nasdaq. The expected delivery of securities is set for January 17, 2025, subject to certain conditions.

Form Type: 8-K

Filing Date: 2025-01-17

Corporate Action: Ipo

Type: New

Accession Number: 000117891325000143

Filing Summary: On January 15, 2025, Silexion Therapeutics Corp entered into a public Offering, selling 2,145,998 ordinary shares and 1,557,705 pre-funded warrants alongside 3,703,703 investor warrants. The Offering closed on or about January 17, 2025, with gross proceeds of approximately $5 million expected. Shares priced at $1.35 each, while pre-funded warrants were $1.3499 each. Pre-Funded Warrants are immediately exercisable at a nominal price, while Investor Warrants last for five years at an exercise price of $1.35. Certain investors signed a Purchase Agreement with typical provisions and agreed on a 60-day standstill post-Offering. H.C. Wainwright acted as the Placement Agent, receiving a 7% fee on gross proceeds. Proceeds are earmarked for pre-clinical studies and corporate purposes. The Offering was conducted per a registration statement (Form S-1) effective January 15, 2025. A press release announcing the pricing was also issued on that date.

Form Type: S-1/A

Filing Date: 2025-01-14

Corporate Action: Ipo

Type: New

Accession Number: 000117891325000100

Filing Summary: Silexion Therapeutics Corp is preparing for an initial public offering (IPO) and has filed the S-1/A form, detailing its operations, financial statements, and other relevant data necessary for the registration. The document highlights significant historical events such as share holdings, the treasury shares status, details on leasehold improvements, and the nature of convertible preferred shares. Additionally, it encompasses the issuance of warrants and options for ordinary shares with specific exercise prices which are crucial for potential investors. The company is particularly focused on raising capital for research and development expenditures while maintaining compliance and operational transparency as it enters the public market.

Form Type: S-1/A

Filing Date: 2025-01-14

Corporate Action: Ipo

Type: New

Accession Number: 000117891325000110

Filing Summary: Silexion Therapeutics Corp filed an S-1/A registration statement on January 14, 2025, indicating plans for an IPO. The IPO aims to raise funds for expanding operations and financing research and development initiatives. The company is priced at less than one US dollar, with specifics on its treasury shares and pre-funded options detailed. The share structure includes various classes of preferred shares and common stock, with comprehensive insights into their respective rights and preferences. The filing includes information on recent financials, share-based payments, and upcoming milestones.

Form Type: CORRESP

Filing Date: 2025-01-14

Corporate Action: Ipo

Type: New

Accession Number: 000117891325000112

Filing Summary: Silexion Therapeutics Corp. has filed a request for the acceleration of the effectiveness of its Registration Statement on Form S-1 (File No. 333-282932), originally filed on January 14, 2024. The company requests that the registration statement become effective at 5:15 p.m., Eastern Time, on January 15, 2025. The request was submitted pursuant to Rule 461 under the Securities Act of 1933. The company has designated Gary Emmanuel from Greenberg Traurig, LLP to receive notifications regarding the effectiveness of the registration statement and has authorized him to modify or withdraw this request.

Form Type: CORRESP

Filing Date: 2025-01-14

Corporate Action: Ipo

Type: Update

Accession Number: 000117891325000114

Filing Summary: Silexion Therapeutics Corp has submitted a request for acceleration of the effective date for its Registration Statement on Form S-1 (Registration No. 333-282932). H.C. Wainwright & Co., LLC, acting as the placement agent, concurs with this request to accelerate the effective date to January 15, 2025, at 5:15 PM Eastern Time. This acceleration request is made pursuant to Rule 461 under the Securities Act, affirming Wainwright's awareness of its obligations related to the best-efforts offering in connection with the Registration Statement.